Halozyme Therapeutics
HALO
Halozyme Therapeutics (HALO) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.28
- EPS estimate
- $1.79
- EPS surprise
- +27.58%
- Revenue surprise
- +19.57%
- Revenue
- $481.0M
- Revenue estimate
- $402.3M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | $1.79 | $2.28 | +27.58% | $481.0M | SEC |
| Q1 2026 | May 11, 2026 | $1.55 | $1.60 | +3.56% | $376.7M | SEC |
| Q4 2025 | Feb 17, 2026 | $2.16 | −$0.24 | −111.11% | $451.8M | SEC |
| Q3 2025 | Nov 3, 2025 | $1.63 | $1.72 | +5.51% | $354.3M | SEC |
| Q2 2025 | Aug 5, 2025 | $1.27 | $1.54 | +21.42% | $325.7M | SEC |
| Q1 2025 | May 6, 2025 | $0.95 | $1.11 | +17.04% | $264.9M | SEC |
| Q4 2024 | Feb 18, 2025 | $1.16 | $1.26 | +8.78% | $298.0M | SEC |
| Q3 2024 | Oct 31, 2024 | $0.99 | $1.27 | +28.11% | $290.1M | SEC |
| Q2 2024 | Aug 6, 2024 | $0.76 | $0.91 | +19.96% | $231.4M | SEC |
| Q1 2024 | May 7, 2024 | $0.69 | $0.79 | +15.08% | $195.9M | SEC |
| Q4 2023 | Feb 20, 2024 | $0.83 | $0.82 | −0.61% | $230.0M | SEC |
| Q3 2023 | Nov 6, 2023 | $0.71 | $0.75 | +6.20% | $216.0M | SEC |
| Q2 2023 | Aug 8, 2023 | $0.63 | $0.74 | +17.46% | $221.0M | SEC |
| Q1 2023 | May 9, 2023 | $0.38 | $0.47 | +22.88% | $162.1M | SEC |
| Q4 2022 | Feb 21, 2023 | $0.30 | $0.42 | +40.61% | $181.5M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.36 | $0.44 | +21.65% | $209.0M | SEC |
| Q2 2022 | Aug 9, 2022 | $0.47 | $0.16 | −65.96% | $152.4M | SEC |
| Q1 2022 | May 10, 2022 | $0.46 | $0.43 | −6.79% | $117.3M | SEC |
| Q4 2021 | Feb 22, 2022 | $0.38 | $0.46 | +19.57% | $102.0M | SEC |
| Q3 2021 | Nov 2, 2021 | $0.42 | $1.48 | +249.47% | $115.8M | — |
Quarterly revenue
Frequently asked questions
When did Halozyme Therapeutics (HALO) last report earnings?
Halozyme Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did HALO beat earnings estimates?
Yes. Halozyme Therapeutics reported EPS of $2.28 for Q2 2026 against a $1.79 estimate — a 27.58% beat.
How much revenue did HALO report last quarter?
Halozyme Therapeutics reported $481.0M in revenue for Q2 2026, against a consensus estimate of $402.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.